Crestline Management’s Celldex Therapeutics CLDX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-295,354	Closed	-$7.46M	–	117
2024 Q4	$7.46M	Buy	295,354 +157,366	+114%	+$4.28M	0.25%	87
2024 Q3	$4.69M	Buy	137,988 +52,637	+62%	+$2.01M	0.24%	112
2024 Q2	$3.16M	Buy	85,351 +16,062	+23%	+$606K	0.25%	113
2024 Q1	$2.91M	Buy	69,289 +2,046	+3%	+$84K	0.26%	113
2023 Q4	$2.67M	Buy	67,243 +4,133	+7%	+$122K	0.23%	121
2023 Q3	$1.74M	Buy	63,110 +21,383	+51%	+$670K	0.2%	114
2023 Q2	$1.42M	Buy	41,727 +11,465	+38%	+$386K	0.15%	124
2023 Q1	$1.09M	Sell	30,262 -6,103	-17%	-$263K	0.13%	123
2022 Q4	$1.62M	Sell	36,365 -3,628	-9%	-$130K	0.24%	80
2022 Q3	$1.12M	Buy	39,993 +1,900	+5%	+$58.2K	0.15%	104
2022 Q2	$1.03M	Buy	38,093 +5,998	+19%	+$174K	0.13%	121
2022 Q1	$1.09M	Buy	+32,095	New	+$1.03M	0.13%	135